Interleukin-33 rescues perivascular adipose tissue anticontractile function in obesity

Am J Physiol Heart Circ Physiol. 2020 Dec 1;319(6):H1387-H1397. doi: 10.1152/ajpheart.00491.2020. Epub 2020 Oct 9.

Abstract

Perivascular adipose tissue (PVAT) depots are metabolically active and play a major vasodilator role in healthy lean individuals. In obesity, they become inflamed and eosinophil-depleted and the anticontractile function is lost with the development of diabetes and hypertension. Moreover, eosinophil-deficient ΔdblGATA-1 mice lack PVAT anticontractile function and exhibit hypertension. Here, we have investigated the effects of inducing eosinophilia on PVAT function in health and obesity. Control, obese, and ΔdblGATA-1 mice were administered intraperitoneal injections of interleukin-33 (IL-33) for 5 days. Conscious restrained blood pressure was measured, and blood was collected for glucose and plasma measurements. Wire myography was used to assess the contractility of mesenteric resistance arteries. IL-33 injections induced a hypereosinophilic phenotype. Obese animals had significant elevations in blood pressure, blood glucose, and plasma insulin, which were normalized with IL-33. Blood glucose and insulin levels were also lowered in lean treated mice. In arteries from control mice, PVAT exerted an anticontractile effect on the vessels, which was enhanced with IL-33 treatment. In obese mice, loss of PVAT anticontractile function was rescued by IL-33. Exogenous application of IL-33 to isolated arteries induced a rapidly decaying endothelium-dependent vasodilation. The therapeutic effects were not seen in IL-33-treated ΔdblGATA-1 mice, thereby confirming that the eosinophil is crucial. In conclusion, IL-33 treatment restored PVAT anticontractile function in obesity and reversed development of hypertension, hyperglycemia, and hyperinsulinemia. These data suggest that targeting eosinophil numbers in PVAT offers a novel approach to the treatment of hypertension and type 2 diabetes in obesity.NEW & NOTEWORTHY In this study, we have shown that administering IL-33 to obese mice will restore PVAT anticontractile function, and this is accompanied by normalized blood pressure, blood glucose, and plasma insulin. Moreover, the PVAT effect is enhanced in control mice given IL-33. IL-33 induced a hypereosinophilic phenotype in our mice, and the effects of IL-33 on PVAT function, blood pressure, and blood glucose are absent in eosinophil-deficient mice, suggesting that the effects of IL-33 are mediated via eosinophils.

Keywords: adipose tissue; diabetes mellitus; hypereosinophilia; hypertension; obesity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipose Tissue / drug effects*
  • Adipose Tissue / metabolism
  • Adipose Tissue / physiopathology
  • Animals
  • Arterial Pressure / drug effects
  • Blood Glucose / drug effects
  • Blood Glucose / metabolism
  • Diabetes Mellitus, Type 2 / metabolism
  • Diabetes Mellitus, Type 2 / physiopathology
  • Diabetes Mellitus, Type 2 / prevention & control
  • Disease Models, Animal
  • Eosinophils / drug effects
  • Eosinophils / metabolism
  • GATA1 Transcription Factor / genetics
  • GATA1 Transcription Factor / metabolism
  • Hypertension / metabolism
  • Hypertension / physiopathology
  • Hypertension / prevention & control*
  • Hypoglycemic Agents / pharmacology
  • Interleukin-33 / pharmacology*
  • Male
  • Mesenteric Arteries / drug effects*
  • Mesenteric Arteries / metabolism
  • Mesenteric Arteries / physiopathology
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Nitric Oxide Synthase Type III / genetics
  • Nitric Oxide Synthase Type III / metabolism
  • Obesity / drug therapy*
  • Obesity / metabolism
  • Obesity / physiopathology
  • Vasodilation / drug effects*
  • Vasodilator Agents / pharmacology*

Substances

  • Blood Glucose
  • GATA1 Transcription Factor
  • Gata1 protein, mouse
  • Hypoglycemic Agents
  • Interleukin-33
  • Vasodilator Agents
  • Nitric Oxide Synthase Type III
  • Nos3 protein, mouse